You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The consortium is made up of Genome Profiling, Rob Knight's UCSD lab, KromaTid, Metabolon, and Orig3n, and is sponsored by a new company called Interome.
The Human Cancer Models Initiative aims to create about 1,000 cancer cell lines that scientists can use to study tumor progression, drug resistance, and more.
TheSTARPlatform includes tools for analyzing genomic data from raw sequence through to variants calls as well as for compressing and storing data.
Consortium researchers will use the STARPlatform to manage whole exome and genome sequence from patients with three diffuse glioma subtypes.
The Food Allergy Science Initiative seeks to supply the basic scientific research needed to spur future development of diagnostics and therapeutics.
The researchers will use Sapientia to analyze samples from 1,000 fetuses as part of efforts to develop an exome-based assay for non-invasive prenatal testing.
MetaSUB researchers will sample high-traffic areas across subway systems, buses, and parks in cities such as New York, San, Francisco, Buenos Aires, Sydney, and London.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The portal offers access to genotype, phenotype, and clinical data related to type 2 diabetes as well as computational tools for querying the information.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.